Home › Esophageal Adenocarcinoma › Virginia › Richmond
Esophageal Adenocarcinoma clinical trials in Richmond, VA
3 studies for Esophageal Adenocarcinoma are looking for participants at sites in and around Richmond (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
RecruitingPhase 2/3
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
RecruitingPhase 3
- Virginia Cancer Institute, Richmond
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
RecruitingPhase 3
- Research Site, Richmond
Esophageal Adenocarcinoma trials in other cities
- New York City, NY18 studies
- Boston, MA13 studies
- Houston, TX12 studies
- Arlington, VA11 studies
- Nashville, TN11 studies
- Durham, NC10 studies
- Baldwin Park, CA9 studies
- Jacksonville, FL9 studies
- Rochester, MN9 studies
- St. Louis, MO9 studies
- Queens, NY9 studies
- Los Angeles, CA9 studies
Other studies in Richmond
- Breast Cancer26 studies
- Non-Small Cell Lung Cancer25 studies
- Prostate Cancer19 studies
- Heart Failure16 studies
- Lung Cancer14 studies
- Cardiovascular Disease13 studies
- Colorectal Cancer13 studies
- Steatotic Liver Disease12 studies
- Acute Myeloid Leukemia12 studies
- Metastatic Cancer12 studies
- Head and Neck Squamous Cell Carcinoma12 studies
- Melanoma11 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.